feladilimab + docetaxel

Feladilimab + docetaxel is an investigational combination therapy comprising feladilimab, an anti-inducible T-cell co-stimulator (ICOS) agonist monoclonal antibody, and docetaxel, a taxane-based chemotherapeutic agent. Feladilimab is designed to activate T-cells by stimulating ICOS, promoting anti-tumor immune responses, while docetaxel inhibits cell division through microtubule stabilization. This combination aims to leverage immunotherapy and chemotherapy for enhanced efficacy in advanced solid tumors. Feladilimab is primarily developed for immunomodulation in oncology, with docetaxel widely used as a cytotoxic agent in various cancer indications.